TransTissue Technologies

Exploring the orthopaedic field for better tissue repair solutions

With over two decades of experience and a strong track record of product development, TransTissue is at the forefront of tissue engineering and regenerative medicine.

Founded in February 2000 as a spin-off of the University Hospital Charité, TransTissue has gone on to become a subsidiary of the BioTissue Group since September 2001. Based in Berlin, the company focuses on researching new methods for tissue regeneration and developing new products for regenerative medicine.

With more than 22 years of collective experience in tissue engineering and regenerative medicine, the scientists at TTT are dedicated to develop innovative solutions for cartilage and osteochondral tissue repair. One of TransTissue’s breakthroughs is a third-generation matrix-induced autologous chondrocyte implant for cartilage tissue replacements, as well as an innovative fourth-generation cell-free absorbable scaffold to repair cartilage defects in synovial joints. These products are manufactured by the BioTissue Group and distributed throughout the EU by a number of European partners.

As a leading player in the tissue engineering field, TransTissue has a proven track record in product development from conception to market maturity. This extensive experience and valuable connections to key opinion leaders in the healthcare industry make them an ideal project partner. Additionally, TransTissue can provide valuable input as a regulatory expert during the development phase and can help identify requirements for the INKplant user cases of meniscus and osteochondral defect.

As a vital partner in INKplant project, TTT brings extensive expertise in cell-based biocompatibility studies, including cell vitality assays, cell metabolism tests, cell migration assays (human and animal), and demographic data analysis. Additionally, as a company with regulatory affairs expertise, TransTissue identifies regulatory obstacles from the beginning of the project to avoid problems. For the distribution of INKplant products, TTT and the BioTissue group can provide a valuable network of potential customers. With state-of-the-art laboratories, a strong background in quality management and regulatory affairs, and an extensive network of university clinics and healthcare institutions, TTT is well-equipped to make a significant impact on the future of regenerative medicine.